Centric Health Resources Presents Third Annual Ultra Orphan Conference 2010, “Emerging Commercialization Strategies for Addressing the Needs of Ultra- Orphan Patients”
September 27 – 29, 2010, The Westin Hotel, St. Louis, Mo.
Invitation Only Event.
Complimentary Registration. Limited Seating. (http://www.centrichealthresources.com/2010Conference/)
CHESTERFIELD, Mo. – August 11, 2010 – With orphan drug development accelerating at an increasing rate, evidenced by a 64 percent increase and the number of orphan drugs designated by the FDA between 2005 and 2009, Centric Health Resources, Inc. presents its Third Annual Ultra Orphan Conference: “Emerging Commercialization Strategies for Addressing the Needs of Ultra-Orphan Patients – Maximize Product Launch and Extend Product Life Cycle One Patient at a Time,” September 27-29, 2010, The Westin Hotel, St. Louis, Mo.
Conference participants, including biopharmaceutical companies, industry consultants, venture capital companies, patient advocacy groups, health plans, employers, and benefits managers will learn how the industry is rethinking, reorganizing, and restructuring.
“We are bringing together high profile industry thought leaders and key influencers who will present opportunities for creating a positive ROI out of a small marketplace and in an environment of health care reform, increasing regulatory requirements, and capital constraints,” says Craig Kephart, president and CEO of Centric, a nationwide, Patient-Centered Health Management® organization dedicated to improving the quality of life for people nationwide with rare, orphan, ultra-orphan, and chronic genetic disorders. “Since orphan drugs follow the same discovery process and timeline as larger drugs, and cost the same amount of money– if not more– it is important for attendees to learn about this vital marketplace and gain new insight into delivering these high-cost, low-volume drugs to patients who desperately need them.”
Centric works with patient advocacy organizations, pharmaceutical companies, biotech firms, and managed care organizations to deliver prescribed therapies and specialized health services.
Pharmaceutical Commerce Magazine is the lead media partner for the conference.
Speakers include:
- Michael McCaughan, editor-in-chief, Prevision Policy, LLC
- Andrew C. von Eschenbach, M.D., senior director for Strategic Initiatives at the Center for Health Transformation; former commissioner for the Food and Drug Administration; and former director of the National Cancer Institute, National Institutes of Health
- Ed Mascioli, M.D., vice president, BioTherapeutics R&D, Orphan and Genetic Diseases, Pfizer, Inc.
- Roger Garceau, M.D., FAAP, senior vice president, R&D and chief medical officer, NPS Pharmaceuticals, Inc.
- Jayson Slotnik, attorney, Foley Hoag, LLP, Washington, D.C.
- Peter Saltonstall, president and CEO, National Organization for Rare Disorders
- Wayne Oliver, vice president and Georgia Project leader, The Center for Health Transformation (CHT)
- David Galardi, Pharm. D., Commercialization, Apogenics, Inc.
- Doug Paul, partner, MME LLC
- Bill Zabel, vice president, U.S. Sales, Talecris Biotherapeutics
- David Sirois, D.M.D., Ph.D., president of the Board of Directors, International Pemphigus & Pemphigoid Foundation (IPPF)
- Craig Kephart, president and CEO, Centric Health Resources, Inc.
Kephart concludes, “This conference provides a forum for industry leaders to advance and elevate market focus on specialty and ultra-orphan drugs, which represent a new frontier in healthcare.”
Conference Registration Qualifications This conference is provided exclusively for biopharmaceutical manufacturers, industry consultants, health plans, patient advocacy groups and venture capital firms. Attendance is by invitation only. Please go to http://www.centrichealthresources.com/2010Conference/ for more information on attending.About Centric Health Resources